Trial Profile
A prospective, single-arm evaluating the efficacy and safety of chidamide, CAG and DLI in patients with high risk or relapse hematological malignancies after allogeneic stem cell transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Aclarubicin (Primary) ; Cytarabine (Primary) ; Tucidinostat (Primary) ; Granulocyte colony-stimulating factors
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Jan 2023 Results (n=12) exploring the efficacy and safety of chidamide and CAG (cytarabine, aclarubicin, and granulocyte colony-stimulating factor) (CCAG) regimen followed by DLI in relapsed AML/MDS after allo HSCT, published in the Medical Oncology
- 20 Aug 2018 New trial record